


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (original): A compound represented by the formula (I):



wherein R^1 is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group;

R^2 and R^3 are independently a hydrogen atom, a halogen atom, a cyano group, a formyl group, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkyloxy group, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted amino group, an optionally substituted carbamoyl group, a carboxyl group, an optionally substituted alkoxy group, an optionally substituted alkoxycarbonyl group, an optionally substituted aryl group, an optionally substituted aryloxy group, an optionally substituted aryloxycarbonyl group, an optionally substituted aralkyl group, an optionally substituted aralkyloxy group, an optionally substituted aroyl group, an optionally substituted arylthio group, an optionally substituted arylsulfinyl group, an optionally substituted arylsulfonyl group, an optionally substituted alkylthio group, an optionally

HiroYuki NAKAHIRA et al.
Atty. Dkt.: Q95145
Preliminary Amendment

substituted alkylsulfinyl group, an optionally substituted alkylsulfonyl group, an optionally substituted heteroaryl group, an optionally substituted heteroarylalkyl group, an optionally substituted heteroarylcarbonyl group, an optionally substituted heteroaryloxy group, an optionally substituted alkylcarbonyl group, an optionally substituted nitrogen-containing saturated heterocyclic group, an optionally substituted aralkyloxycarbonyl group, an optionally substituted cycloalkyloxycarbonyl group, a tetrahydrofuranyloxycarbonyl group, a cinnamyloxycarbonyl group, or a group represented by the formula: $-\text{C}(\text{O})\text{OCH}(\text{R}^{18})\text{OC}(\text{O})\text{R}^{19}$ wherein R^{18} is a hydrogen atom, an alkyl group, an alkenyl group, a cycloalkyl group or an alkoxy group, and R^{19} is an optionally substituted alkyl group, an optionally substituted alkenyl group, a cycloalkyl group, a cycloalkyloxy group, an optionally substituted alkoxy group, an optionally substituted alkenyloxy group, a 2-indanyloxy group, a 5-indanyloxy group or an optionally substituted aryloxy group, or R^2 and R^3 may be taken together to form an oxo group on the ring;

R^4 and R^5 are independently a hydrogen atom, a halogen atom, an optionally substituted alkyl group or an alkoxycarbonylmethyl group;


R^3 and R^5 may be taken together to form a double bond on the ring;

R^2 , R^3 , R^4 and R^5 may form an optionally substituted benzene ring, an optionally substituted cycloalkene ring or an optionally substituted 5-or 6-membered heteroaromatic ring together with the adjacent carbon atoms;


R^6 is a hydrogen atom, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted vinyl group, an

optionally substituted nitrogen-containing saturated heterocyclic group or an optionally substituted heteroaryl group; and

—Y—NH₂ is a group represented by the following formula (A) or a group represented by the following formula (B):



wherein m is 0, 1 or 2, and R⁷ is absent or one or two R⁷'s are present and are independently a halogen atom, a hydroxyl group, an oxo group, an optionally substituted alkoxy group, an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted aralkyl group, an optionally substituted amino group, a carboxyl group, an optionally substituted alkoxycarbonyl group or an optionally substituted carbamoyl group, or two R⁷'s, when taken together, represent methylene or ethylene and may bind to two carbon atoms constituting the ring, to form a new ring, or



wherein n is 0, 1 or 2, and R⁸ is absent or one or two R⁸'s are present and are independently a halogen atom, a hydroxyl group, an oxo group, an optionally substituted alkoxy group, an optionally substituted alkyl group, an optionally substituted aryl group, an optionally substituted aralkyl group, an optionally substituted amino group, a carboxyl group, an optionally substituted

alkoxycarbonyl group or an optionally substituted carbamoyl group, or two R⁸s, when taken together, represent methylene or ethylene and may bind to two carbon atoms constituting the ring, to form a new ring,

a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug.

2. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 1, wherein –Y–NH₂ is a group represented by the formula (A) and m is 1 or 2, or –Y–NH₂ is a group represented by the formula (B) and n is 1 or 2.

3. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 1 or 2, wherein R² and R³ are taken together to form an oxo group on the ring.

4. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 1 or 2, wherein R³ and R⁵ are taken together to form a double bond on the ring.

5. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 1 or 2, wherein R², R³, R⁴ and R⁵ form an optionally substituted benzene ring, an optionally substituted cycloalkene ring or an optionally substituted 5-or 6-membered heteroaromatic ring together with the adjacent carbon atoms.

6. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 4, wherein R² is a hydrogen atom, a cyano group,

Hiroiyuki NAKAHIRA et al.
Atty. Dkt.: Q95145
Preliminary Amendment


an optionally substituted alkyl group, a carboxyl group, an optionally substituted alkoxy group, an optionally substituted alkoxycarbonyl group, an optionally substituted cycloalkyloxycarbonyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted aryloxy group, an optionally substituted aryloxycarbonyl group, an optionally substituted aralkyl group, an optionally substituted aralkyloxy group, an optionally substituted aroyl group, an optionally substituted alkylcarbonyl group, a tetrahydro-furanyloxycarbonyl group, a cinnamyloxycarbonyl group, or a group represented by the formula: $-C(O)OCH(R^{18})OC(O)R^{19}$ wherein R^{18} and R^{19} are as defined in claim 1.

7. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 4, wherein R^4 is a hydrogen atom or a methyl, ethyl or alkoxycarbonylmethyl group.

8. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 4, wherein R^2 is a hydrogen atom, a cyano group, an optionally substituted alkyl group, a carboxyl group, an optionally substituted alkoxy group, an optionally substituted alkoxycarbonyl group, an optionally substituted cycloalkyloxycarbonyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted aryloxy group, an optionally substituted aryloxycarbonyl group, an optionally substituted aralkyl group, an optionally substituted aralkyloxy group, an optionally substituted aroyl group, an optionally substituted alkylcarbonyl group, a tetrahydro-furanyloxycarbonyl group, a cinnamyloxycarbonyl group, or a group represented by the formula:

$-\text{C}(\text{O})\text{OCH}(\text{R}^{18})\text{OC}(\text{O})\text{R}^{19}$ wherein R^{18} and R^{19} are as defined in claim 1; and R^4 is a hydrogen atom or a methyl, ethyl or alkoxycarbonylmethyl group.

9. (currently amended): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to ~~any one of claims 1 to 8~~claim 1, wherein R^6 is a group represented by the following formula (C), (D) or (E):



wherein Z is an oxygen atom, $-\text{S}(\text{O})_p$ or $-\text{N}(\text{R}^{14})-$,

R^9 is absent or one or two R^9 s are present and are independently a halogen atom, a hydroxyl group, a formyl group, a carboxyl group, a cyano group, an alkylthio group, an alkylsulfinyl group, an alkylsulfonyl group, an alkyl group, a haloalkyl group, a cycloalkyl group, an alkoxy group, a haloalkoxy group, an optionally substituted amino group, an optionally substituted carbamoyl group, an alkoxycarbonyl group, an optionally substituted alkylcarbonyl group, a cycloalkylcarbonyl group, an optionally substituted aryl group, or an optionally substituted heteroaryl group, or two R^9 s, when taken together, represent a C_{1-3} alkylenedioxy group,

R^{10} is absent or one or two R^{10} s are present and are independently a halogen atom, a cyano group, an alkyl group, a haloalkyl group, a cycloalkyl group, an alkoxy group or a haloalkoxy group,

R^{11} is methyl, ethyl, a chlorine atom or a bromine atom,

R^{12} is a hydrogen atom, methyl, ethyl, a chlorine atom or a bromine atom,

R^{13} is a hydrogen atom, methyl or ethyl,


p is 0, 1 or 2, and

R^{14} is a hydrogen atom or an alkyl group.

10. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 9, wherein R^6 is the formula (C) or the formula (E).

11. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 10, wherein R^6 is the formula (C), and R^9 is absent or one or two R^9 's are present and are independently a halogen atom, a cyano group, an alkylthio group, an alkylsulfonyl group, a C_{1-3} alkylenedioxy group, an alkyl group, a haloalkyl group, a cycloalkyl group, an alkoxy group, a haloalkoxy group, an alkoxycarbonyl group, an alkylcarbonyl group, a haloalkylcarbonyl group or a cycloalkylcarbonyl group.

12. (currently amended): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to ~~any one of claims 1 to 8~~claim 1, wherein R^6 is the following formula (F):



Hiroiyuki NAKAHIRA et al.
Atty. Dkt.: Q95145
Preliminary Amendment

wherein R¹⁵ is a halogen atom, a cyano group, an alkyl group, a haloalkyl group, a cycloalkyl group, an alkoxy group or a haloalkoxy group, and R¹⁶ is a hydrogen atom or a fluorine atom.

13. (currently amended): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to ~~any one of claims 1 to 12~~claim 1, wherein R¹ is a hydrogen atom or an optionally substituted alkyl group of 1 to 3 carbon atoms whose substituent(s) is selected from fluorine atom, optionally substituted aroyl groups, carboxyl group, optionally substituted alkoxy carbonyl groups, optionally substituted aryl groups and optionally substituted aryloxy groups.

14. (currently amended): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to ~~any one of claims 1 to 12~~claim 1, wherein R¹ is a group represented by the formula: -Ra-Rb-Rc in which


Ra is an alkylene chain,

Rb is a single bond or a carbonyl group, and

Rc is an optionally substituted alkyl group, an optionally substituted alkoxy group, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted aryloxy group or an optionally substituted heteroaryloxy group.

15. (currently amended): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to ~~any one of claims 1 to 12~~claim 1, wherein R¹ is a hydrogen atom, methyl or ethyl.


16. (original): A compound according to claim 1, which is represented by the formula (II):



wherein R^4 is as defined in claim 1; R^{15} and R^{16} are as defined in claim 12; R^{1a} is a hydrogen atom, methyl or the formula: $-Ra-Rb-Rc$ wherein Ra , Rb and Rc are as defined in claim 14; and R^{2a} is a cyano group, a carboxyl group, an oxazolyl group, an optionally substituted alkoxycarbonyl group, an optionally substituted cycloalkyloxycarbonyl group, a tetrahydrofuranyloxycarbonyl group, an optionally substituted aryloxycarbonyl group, a cinnamyloxycarbonyl group, or a group represented by the formula: $-C(O)OCH(R^{18})OC(O)R^{19}$ wherein R^{18} and R^{19} are as defined in claim 1,

a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug.

17. (original): A compound according to claim 1, which is represented by the formula (III):




wherein R^{16} is as defined in claim 12; R^{1a} and R^{2a} are as defined in claim 16; and R^{15a} is a chlorine atom, a bromine atom, an iodine atom, a cyano group, methyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy or trifluoromethoxy, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug.

18. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 17, wherein R^{1a} is a hydrogen atom.

19. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 17 or 18, wherein R^{2a} is a carboxyl group, an optionally substituted alkoxycarbonyl group, or a group represented by the formula: $-C(O)OCH(R^{18})OC(O)R^{19}$ wherein R^{18} and R^{19} are as defined in claim 1.


20. (original): A compound according to claim 1, which is represented by the formula (IV):



wherein R^1 , R^6 and Y are as defined in claim 1; and the ring A is an optionally substituted benzene ring, an optionally substituted cycloalkene ring or an optionally substituted 5-or 6-membered heteroaromatic ring,

a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug.

21. (original): A compound according to claim 1, which is represented by the formula (V):




wherein R¹ is as defined in claim 1; R¹⁶ is as defined in claim 12; R^{15a} is as defined in claim 17; and A is as defined in claim 20,

a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug.

22. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 21, wherein R¹ is a hydrogen atom or methyl.

23. (original): A compound according to claim 1, which is represented by the formula (VI):



Hiroyuki NAKAHIRA et al.
Atty. Dkt.: Q95145
Preliminary Amendment

wherein R^1 is as defined in claim 1; R^{16} is as defined in claim 12; R^{15a} is as defined in claim 17; and R^{17} is absent or one to four R^{17} s are present and are independently a hydroxyl group, a halogen atom, a cyano group, a carboxyl group, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted cycloalkyloxy group, an optionally substituted alkenyl group, an optionally substituted carbamoyl group, an optionally substituted alkoxy group, an optionally substituted alkoxycarbonyl group, an optionally substituted aryloxy carbonyl group, an optionally substituted alkyl carbonyl group, an optionally substituted cycloalkyloxy carbonyl group, an optionally substituted aralkyloxy carbonyl group, a tetrahydrofuranyloxy carbonyl group, a cinnamyloxy carbonyl group, or a group represented by the formula: $-C(O)OCH(R^{18})OC(O)R^{19}$ wherein R^{18} and R^{19} are as defined in claim 1,

a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug.

24. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 23, wherein R^1 is a hydrogen atom, methyl or the formula: $-Ra-Rb-Rc$ wherein Ra , Rb and Rc are as defined in claim 14.

25. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 23, wherein R^1 is methyl.

26. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 25, wherein R^{17} is a fluorine atom, a chlorine atom, a cyano group, a carboxyl group, acetyl, dimethylcarbamoyl, diethylcarbamoyl, methyl, ethyl, isopropyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, isopropoxy,

HiroYuki NAKAHIRA et al.
Atty. Dkt.: Q95145
Preliminary Amendment

difluoromethoxy, trifluoromethoxy, an alkoxyalkyl group optionally substituted by a halogen atom or a hydroxyl group, an optionally substituted alkoxycarbonyl group, an optionally substituted cycloalkyloxycarbonyl group, a tetrahydrofuranyloxycarbonyl group, a cinnamyloxycarbonyl group, or a group represented by the formula: $-C(O)OCH(R^{18})OC(O)R^{19}$ wherein R^{18} and R^{19} are as defined in claim 1.

27. (original): A compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to claim 25, wherein R^{17} is a fluorine atom, a cyano group, a carboxyl group, an alkoxymethyl group optionally substituted by a halogen atom, an optionally substituted alkoxycarbonyl group, an optionally substituted cycloalkyloxycarbonyl group, a tetrahydrofuranyloxycarbonyl group, a cinnamyloxycarbonyl group, or a group represented by the formula: $-C(O)OCH(R^{18})OC(O)R^{19}$ wherein R^{18} and R^{19} are as defined in claim 1.

28. (currently amended): A dipeptidyl peptidase IV inhibitor comprising a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to ~~any one of claims 1 to 27~~claim 1 as an active ingredient.

29. (currently amended): A pharmaceutical composition for the treatment of diabetes comprising a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to ~~any one of claims 1 to 27~~claim 1 as an active ingredient.

30. (currently amended): Use of a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to ~~any one of claims 1 to 27~~claim 1 in the manufacture of a dipeptidyl peptidase IV inhibitor.

Hiroiyuki NAKAHIRA et al.
Atty. Dkt.: Q95145
Preliminary Amendment

31. (currently amended): Use of a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to ~~any one of claims 1 to 27~~claim 1 in the manufacture of a pharmaceutical composition for the treatment of diabetes.

32. (currently amended): A method for treating diabetes comprising administering an effective amount of a compound, a prodrug thereof or a pharmaceutically acceptable salt of the compound or prodrug according to ~~any one of claims 1 to 27~~claim 1 to a patient who needs treatment.